Wu J et al. (2024) COMPARATIVE ANALYSIS OF SERUM LIPID PROFILES IN ATHLETES: DISTINGUISHING BETWEEN NONALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS. Revista Internacional de Medicina y Ciencias de la Actividad Física y el Deporte vol. 24 (98) pp. 362-376.
DOI: https://doi.org/10.15366/rimcafd2024.98.024

ORIGINAL

COMPARATIVE ANALYSIS OF SERUM LIPID PROFILES IN ATHLETES: DISTINGUISHING BETWEEN NONALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS

Xiaping Liu[1], Jinlong Wu[2,*], Xiangyan Chen[3], Linhong Su[1], Jian Chen[1], Xiaoqu Zhu[1]

[1] Department of Infectious (Liver) Disease, Wenzhou Hospital of Chinese Medicine, Wenzhou 325000, Zhejiang Province, China.
[2] Associate Chief Physician, Department of Rehabilitation Medicine, Wenzhou Hospital of Chinese Medicine, Wenzhou 325000, Zhejiang Province, China.
[3] Department of Gynecology, Wenzhou Hospital of Chinese Medicine, Wenzhou 325000, Zhejiang Province, China.
E-mail: hokinglong@163.com

Recibido 23 de enero de 2024 **Received** January 23, 2024
Aceptado 24 de septiembre de 2024 **Accepted** September 24, 2024

ABSTRACT

Objective: To explore the differences in serum lipidomic profiles between athletes diagnosed with nonalcoholic fatty liver disease (NAFLD) and those with nonalcoholic steatohepatitis (NASH), highlighting potential implications for athlete health and performance. Methods: A retrospective analysis was conducted on 40 athletes treated at our sports medicine clinic from January 2021 to December 2022. Participants were divided into two groups: those with NASH (n=18) and those with nonalcoholic simple fatty liver (NAFL) (n=22). Various metabolic and inflammatory markers were compared, including systolic and diastolic blood pressure, liver enzymes, lipid profiles, inflammatory cytokines (interleukin-6, tumor necrosis factor-alpha), and lipidomic profiles. **Results:** The study included 40 athletes, with no significant differences in gender, age, disease progression, or body mass index between the two groups. Liver stiffness measurements were significantly higher in the NAFL group. Both groups exhibited similar blood pressure and alanine aminotransferase levels; however, the NASH group showed elevated alkaline phosphatase levels. No significant differences were found in total cholesterol, triglycerides, or HDL cholesterol levels. The NASH group exhibited higher levels of inflammatory markers such as IL-6 and TNF-alpha and showed distinct lipidomic signatures

compared to the NAFL group, with significant variations in certain phosphatidylcholines (PC), phosphatidylethanolamines (PE), and triglycerides (TG). **Conclusion:** The serum lipidomic analysis reveals distinct metabolic characteristics between athletes with NAFL and those with NASH, suggesting that specific lipid biomarkers may aid in differentiating these conditions in athletes. Understanding these differences is crucial for developing targeted interventions to manage liver health in athletes, optimizing their performance and recovery by addressing underlying metabolic disturbances.

KEYWORDS: Nonalcoholic simple fatty liver disease; Nonalcoholic steatohepatitis; Serum lipomics; comparative analysis

1. INTRODUCTION

In sports medicine, liver health remains a critical yet often overlooked aspect of overall athlete wellness and performance. Nonalcoholic Fatty Liver Disease (NAFLD) and its more severe form, Nonalcoholic Steatohepatitis (NASH), represent significant health concerns not only in the general population but also among athletes, particularly those in sports where diet and body composition are closely managed. Understanding how these conditions manifest in athletes, who are generally considered to be at the pinnacle of health and fitness, is crucial for effective management and prevention strategies(Abdelmalek, 2021). NAFLD is characterized by the accumulation of fat in liver cells in individuals who consume little to no alcohol, while NASH is a progression of NAFLD that includes liver inflammation and damage.

The presence of these conditions can lead to serious complications such as cirrhosis, liver failure, and increased risk of cardiovascular disease. In athletes, the impact of NAFLD and NASH can extend to performance decrement, reduced recovery capacity, and prolonged fatigue, all of which can critically undermine athletic output and career longevity. (Polyzos, kountouras, & mantzoros, 2020 Mar). Serum lipidomics, the comprehensive analysis of lipid species in blood, provides a unique window into metabolic health and disease states. In the realm of liver disease, particularly NAFLD and NASH, changes in serum lipid profiles can reflect early alterations in liver metabolism and function, even before clinical symptoms become apparent. For athletes, whose dietary and metabolic profiles differ significantly from the general population, understanding these lipidomic signatures could aid in early diagnosis and personalized management strategies(Younossi et al., 2019).

The primary objective of this study is to conduct a comparative analysis of serum lipidomic profiles between athletes diagnosed with NAFLD and those with NASH. This analysis seeks to identify specific lipid biomarkers that differentiate these conditions, potentially aiding in more precise and early diagnosis(Pierantonelli & Svegliati-Baroni, 2019). Furthermore, understanding

these differences can help tailor dietary and training programs to better manage or prevent liver-related metabolic disturbances in athletes.

This study employs a retrospective design, analyzing existing clinical data from athletes treated for NAFLD and NASH within a defined period. By comparing biochemical, metabolic, and inflammatory markers, along with detailed lipidomic profiles, the study aims to elucidate the underlying differences in disease mechanisms between NAFLD and NASH in an athletic population. This approach not only enhances our understanding of how these liver conditions affect athletes differently but also contributes to the broader field of sports nutrition and preventive health care(Suppli et al., 2019).

Through detailed serum lipidomic analysis, this research anticipates contributing significantly to the fields of sports medicine, hepatology, and metabolic health. By identifying lipidomic signatures specific to NAFLD and NASH in athletes, the findings could lead to the development of targeted interventions that improve liver health and overall athletic performance. Additionally, this study sets the stage for future prospective research that could explore the longitudinal effects of dietary and training interventions on liver health outcomes in athletes (Sun & Choi, 2023).

2. Data and Methods

2.1 Research Objects

A retrospective study of 40 patients with nonalcoholic fatty liver disease in our hospital from January 2021 to December 2022 was conducted, including 17 male patients and 23 female patients, ranging from 30 to 60 years, with an average age of (49.66 ± 6.34) years. Our institution's ethics review board has given their blessing to this research. Criteria for inclusion: All patients with nonalcoholic fatty liver disease met the diagnostic criteria in the "Guidelines for the diagnosis and treatment of non-alcoholic fatty liver disease (2018 Revision)" (De & Duseja, 2020) after examination by a professional physician.

① The near-field echo of the liver showed "bright liver" changes; ② All patients had a certain degree of metabolic syndrome; ③ The far-field echo of the patients' liver was weak; ④ The serum liver enzymes of the patients were significantly increased; ⑤ Intrahepatic duct structure is not clearly displayed; ⑥ The patients and their families were informed and agreed to the study. Exclusion criteria: ① Those with viral hepatitis and specific fatty liver disease; ② Patients who had ketoacidosis and diabetic foot with infection in recent half a year; ③ Patients who have taken drugs that affect fat metabolism in recent 2 weeks; ④ Those with acute massive cerebral infarction and other acute stress state of the body; ⑤ Women during pregnancy and lactation; ⑥ Alcoholics and drug abusers.

2.2 Methods

2.2.1 Patient Data Collection

All individuals with fever underwent a liver biopsy, and the liver biopsy grading system (Sberna et al., 2018) of SAF was used for pathological diagnosis and grouping. Patients were classified as having either non-alcoholic simple fatty liver (NAFL) or non-alcoholic steatohepatitis (NASH) according to the severity of their liver disease. The patients who were chosen had their medical histories collected, which included information such as their gender, age, illness progression, body mass index, anthropometric indicators, liver stiffness, blood routine, and so on.

2.2.2 Lipoomic Analysis

All patients were forbidden to drink alcohol two days before blood sample collection, and the blood collection site should be cleaned to avoid wound infection, too small cuff of coat, and subcutaneous hematoma. The patients were fasting for more than 8 hours. Blood samples were collected from the median elbow vein in the morning, centrifuged with a centrifuge at the speed of 3500rpm for 10 minutes, after that, one hundred microliters of the supernatant were removed. In addition to this, 900 μL of a distillate made from 100% isopropanol was poured into the centrifuge container, and was subjected to ultrasonic treatment after vortex vibration at room temperature. Finally, the supernatant was taken for detection after centrifugation for 10 minutes. The 100% isopropanol extract was used as the blank control group, 20ml of each sample was taken and mixed as the quality control sample, and the serum lipid was analyzed by ultra-high liquid chromatography (Waters ACQUITY UPLCI－Class liquid phase system, American Waters, Inc), the chromatographic column was ACQUITY UPLC series, the filling type was CSH C18, the filling particle size was 1.7 μ m, the pore size was 130 μ m, the specification was 1mm x 50mm, and the 1 / PKG time-of-flight mass spectrometry system. The column temperature was 55 ℃, the flow rate was 0.4ml/min, and Mobile Phase A: acetonitrile: water = 3:2. Mobile phase B: isopropanol: acetonitrile = 9:1. The mobile phase a/b contained ammonium formate (10mmol/l). Methods and conditions of mass spectrometry analysis: molecular weight scanning ranged from 50 to 2000m/z, ion source: electrospray ionization source(ESI); capillary voltage: 3KV; taper hole voltage: 25V; collision energy: 15-60v; source temperature: 120 ℃; desolvent temperature: 500 ℃; cone hole gas velocity: 50l/h; desolvent gas velocity: 800l/h; scanning time: 0.2S; leucine enkephalin (m/z positive ion: 556.2771; negative ion: 554.2615) was corrected in real time. Injection flow rate was 10 μ L/min.

2.3 Observation Indicators

1) Gender, age, disease progression, body mass index, and liver

stiffness were examined between NASH and NAFL cases.

(2) Patients in both groups had their systolic and diastolic blood pressure, as well as their alkaline phosphatase (ALP) and alanine aminotransferase (ALT) levels evaluated.

(3) Patients in both groups had their uric acid, total cholesterol, triglyceride, and high-density lipoprotein cholesterol levels analyzed.

(4) Patients in both groups had their amounts of interleukin-6 (IL-6), tumor necrosis factor- (TNF-), and arachidonic acid (AA) analyzed.

(5) Comparisons were made between the two groups using the neutrophil-to-lymphocyte ratio (NLR), neutrophil-to-absolute-lymphocyte ratio (NAFL), and the NASH index. The severity of liver fibrosis was favorably associated with NAFL level. Any time the total was negative one 414, it was in progressive cirrhosis. When the score was greater than 0.676, it was at the stage of progressive liver fibrosis.

(6) The two groups of lipomics were compared: the variable weight value (VIP) was calculated according to OPLSDA model. When VIP > 1, it indicates that there were lipid metabolites with obvious concentration changes in serum samples.

2.4 Statistical Treatment

SPSS20.0 was used for the statistical analysis and data summarization of the research. Different groups' assessment results were presented as ($\bar{x} \pm s$), and the results were obtained by t-test. Count / grade data were expressed in "%" and chi square obtains the results. If there was a statistically significant difference between the two sets of data, the expression form was $p < 0.05$. The substances with $P < 0.05$ and VIP > 1 were selected as the differential lipid components between the groups

3. Results

3.1 Basic data of NASH and NAFL cases

Forty patients were diagnosed with nonalcoholic fatty liver disease, including 18 patients with nonalcoholic steatohepatitis (NASH) and 22 patients with nonalcoholic fatty liver disease (NAFL). The NASH group and the NAFL group did not differ significantly from one another in terms of gender, age, progression of illness, or body mass index, according to the statistical analysis ($P > 0.05$). It was statistically significant that the liver stiffness of patients in the NAFL group was higher than that of patients in the NASH group ($P < 0.05$). See Table 1.

Table 1: Basic data of NASH and NAFL cases

GROUP	GENDER		AGE (YEARS)	COURSE OF DISEASE (YEARS)	BODY MASS INDEX (KG/M2)	LIVER HARDNESS (KPA)
	MALE	FEMALE				
NASH GROUP (N=18)	8	10	52.21 ± 10.33	3.66 ± 1.24	32.17 ± 6.25	12.34 ± 3.11
NAFL GROUP (N=22)	9	13	53.17 ± 9.77	3.17 ± 1.19	31.44 ± 4.32	17.28 ± 4.16
T/X2	0.05		0.30	1.27	0.44	4.17
P	0.822		0.765	0.211	0.66	0.000



Figure 1: Comparison of basic information of patients in NASH group and NAFL group

3.2 Comparison of SBP, DBP, ALP and ALT of patients between the two groups.

There was no statistically significant difference between the NASH group and the NAFL group of individuals in terms of their systolic blood pressure, diastolic blood pressure, or ALT levels (P > 0.05), but the ALP level of patients in the NASH group was higher than NAFL group, with statistical significance (P < 0.05), as shown in Table 2.

Table 2: Patients' SBP, DBP, ALP, and ALT between groups

GROUP	SBP (MMHG)	DBP (MMHG)	ALP (U/L)	ALT (U/L)
NASH GROUP (N=18)	144.61 ± 14.71	85.67 ± 13.38	98.78 ± 29.67	41.83 ± 18.01
NAFL GROUP (N=22)	141.27 ± 14.37	84.64 ± 12.51	82.95 ± 18.65	31.32 ± 16.38
T	0.72	0.25	2.06	1.63
P	0.474	0.802	0.000	0.112



Figure 2: Comparison of SBP, DBP, ALP and ALT of patients between the two groups

3.3 UA, TC, TG, and HDL-C comparison between groups

The amounts of HDL-C, UA, TC, and TG in individuals were not significantly different between the two groups according to statistical analysis (P > 0.05), see Table 3.

Table 3: UA, TC, TG, and HDL-C comparison between groups

GROUP	UA (M MOL/L)	TC (MMOL/L)	TG (MMOL/L)	HDL-C (MMOL/L)
NASH GROUP (N=18)	321.28 ± 96.25	4.17 ± 1.08	2.07 ± 0.97	0.66 ± 0.34
NAFL GROUP (N=22)	319.63 ± 99.46	4.07 ± 1.02	2.37 ± 1.06	0.91 ± 0.41
T	0.05	0.30	0.92	2.07
P	0.958	0.766	0.361	0.045



Figure 3: The two groups' UA, TC, TG, and HDL-C values were compared

3.4 Comparing patient IL-6, TNF-α, and AA values between groups

There was a statistically significant difference between the amounts of IL-6 and TNF- in the NASH group and those in the NAFL group. The NASH group had substantially greater levels of both ($P < 0.05$). There was a statistically significant difference between the levels of AA in the NASH group and those in the NAFL group. The NASH group had a substantially reduced level of AA ($P < 0.05$). See Table 4.

Table 4: Comparing patient IL-6, TNF-α, and AA values between groups

GROUP	IL-6 (PG/ML)	TNF- A (PG/ML)	AA (NG/ML)
NASH GROUP (N=18)	47.85 ± 6.25	56.74 ± 5.62	1375.66 ± 501.85
NAFL GROUP (N=22)	40.07 ± 7.37	49.22 ± 9.09	1924.51 ± 689.00
T	3.55	3.06	2.82
P	0.000	0.004	0.008



Figure 4: IL-6, TNF-α, and AA levels of subjects in the two groups were compared

3.5 Comparison of NLR value, NASH score and NAFL score of patients in the two groups

There was not a statistically significant difference between the two groups of individuals with regard to their NLR levels or their NAFL scores ($P > 0.05$), however, the NASH score for the NASH group was significantly greater

than that of the NAFL group, and this disparity was statistically significant (P < 0.05). See Table 5.

Table 5: Comparison of NLR value, NASH score and NAFL score of patients in the two groups

GROUP	NLR	NASH SCORE	NAFL SCORE
NASH GROUP (N=18)	2.21 ± 0.90	75.52 ± 22.41	60.19 ± 16.28
NAFL GROUP (N=22)	2.44 ± 0.94	50.19 ± 15.37	55.18 ± 15.97
T	0.78	4.23	0.98
P	0.437	0.000	0.334



Figure 5: Comparison of NLR value, NASH score and NAFL score of patients in the two groups

3.6 Lipomics Analysis

A total of 792 lipids were detected in the serum of all samples, and the VIP value of 98 substances was > 1. The detected substances were analyzed and verified. Finally, there were 23 lipids with statistically significant difference between the two groups (P < 0.05).

The levels of 5 kinds of PC, 4 kinds of PE, 1 kind of PS, 2 kinds of TG, 3 kinds of sphingomyelin (SM) and 1 kind of glucose ceramide of patients in NASH group were higher than those in NAFL group, and the levels of 6 kinds of TG and 1 kind of PC in NASH group were lower than those in NAFL group, and the difference was statistically significant (P < 0.05), see Table 6.

Table 6: (a) Analysis of lipomics difference between the two groups

GROUP	PC (32:1)	PC (35:4)	PC (36:5)	PC (38:3)	PC (38:6)	PC (44:5)	TG (52:1)	TG (54:2)	TG (52:4)	TG (54:4)	TG (57:6)	TG (58:4)	TG (60:6)
NASH/NAFL	1.102	1.202	1.237	1.102	0.846	1.342	1.429	1.286	0.798	0.804	0.794	0.737	0.789
VIP VALUE	1.368	6.279	2.966	1.409	1.960	4.741	2.942	2.567	6.056	4.763	4.445	1.566	1.461
T/Z	1.380	3.390	2.115	2.253	2.028	2.192	3.789	1.914	2.138	2.077	2.220	1.982	2.337
P	＜ 0.001	＜ 0.001	＜ 0.001	＜ 0.001	＜ 0.001	＜ 0.001	＜ 0.001	＜ 0.001	＜ 0.001	＜ 0.001	＜ 0.001	＜ 0.001	＜ 0.001

Table 6: (b) Analysis of lipomics difference between the two groups

GROUP	TG (54:5)	PE (34:1)	PE (36:2)	PE (38:1)	PE (39:1)	SM (37:1)	SM (39:1)	SM (40:1)	GLCCER 40:2)	PS (33：0)
NASH/NAFL	0.795	1.122	1.325	1.207	1.313	1.429	1.286	0.798	0.804	1.130
VIP VALUE	1.177	3.033	1.602	2.380	3.150	2.942	2.567	6.056	4.763	1.108
T/Z	2.431	2.062	2.766	3.466	3.149	3.789	1.914	2.138	2.077	2.480
P	＜ 0.001	＜ 0.001	＜ 0.001	＜ 0.001	＜ 0.001	＜ 0.001	＜ 0.001	＜ 0.001	＜ 0.001	＜ 0.001

4. Discussion

The histopathology of nonalcoholic fatty liver disease can range from uncomplicated steatosis, also known as nonalcoholic fatty liver disease, to more serious conditions such as nonalcoholic steatohepatitis, liver cirrhosis, and hepatocellular carcinoma. Nonalcoholic steatohepatitis also needs hepatocyte degeneration inflammation with or without fibrosis. Therefore, hepatocyte degeneration inflammation is a sign of nonalcoholic steatohepatitis, in which steatosis can be bullous or mixed. However, the presence of microbubble steatosis has brought problems to the diagnosis of the disease. Therefore, an effective disease diagnosis is convenient for early intervention of the disease (Mehra & Chauhan, 2017; Yu, Chen, Mo, Guo, & Liu, 2020; Zhang et al., 2018). The exact mechanisms behind the development of nonalcoholic fatty liver disease are not yet completely understood. It is commonly said that in the state of insulin resistance, the lipolysis function is abnormally increased, the cholesterol content is increased, resulting in the accumulation of fat in the liver, a large number of triglycerides are generated, which makes the function of fatty tissue in the liver disordered, produces toxic substances, leads

to the secretion of a variety of inflammatory factors, causes hepatocyte necrosis, thus affecting liver function, causing that NAFL will finally progress to NASH (Bessone, Razori, & Roma, 2019; Maurice, 2018; Mendez-Sanchez et al., 2018; Simon et al., 2019). Some experts have suggested that the rapid absorption of fatty acids will cause intestinal dysfunction (Liu, Wang, He, Xu, & Gong, 2019; Männistö et al., 2019; Mato, Alonso, & noureddin, 2019; Pirola & Sookoian, 2022; Sargazi et al., 2023), thereby increasing the activation in addition to the discharge of inflammation factors like interleukin-6 and tumor necrosis factor-. The results of this study showed that there was a statistically significant difference between the amounts of IL-6 and TNF- in the NASH group and those in the NAFL group. The NASH group had substantially greater levels of both ($P < 0.05$). There was a statistically significant difference between the levels of AA found in the NASH group and those found in the NAFL group ($P < 0.05$), indicating that in NAFLD patients, peripheral adipose tissue dysfunction, accompanied by subsequent lipotoxicity, can promote the production of pro-inflammatory factors, make the body in the chronic inflammatory state, and lipotoxicity mediates cell apoptosis, which is one of the related factors to promote the progress of NASH. At present, studies have confirmed that the cytokines produced by the liver can promote the progress of steatohepatitis, make a large number of hepatocytes apoptosis, change the pathological state of NASH, and increase the level of TNF- α in liver tissue, and progress from simple fatty liver to steatohepatitis (Khalifa, Errafii, Al-Akl, & Arredouani, 2020; Zaiou, 2022). Phospholipids are one of the main components of biofilms, which are divided into glyceryl phosphatide and sphingomyelin. According to the polar head group, they can be divided into PC, PG, PE, PS and PI and others. In the human body, PC and PE are relatively abundant. PC is mainly synthesized through choline pathway, and is absorbed in the small intestine in the form of lysophosphatidylcholine(LPC). After entering hepatocytes, choline is rapidly phosphorylated, and then reacts with cytidine triphosphate (CTP). Under the catalysis of transferase, diacylglycerol is synthesized to form PC. When damaged, it will lead to the failure of TAG binding in the liver, resulting in the accumulation of TAG in the liver and the damage of liver function (Rusu et al., 2022; Wong, Tsang, & Ng, 2018; Yela, Faber, Dantas, Benetti-pinto, & Jales, 2022; J. Zhou et al., 2023; Q. Zhou, Zhang, Wang, & Liu, 2019). The inflammatory cytokines tumor necrosis factor-alpha (TNF-), interleukin-6 (IL-6), and interleukin-10 (IL-10) have been shown to be suppressed and can weaken the infiltration of macrophages, reduce neutrophil mediated microcirculation, and induce cell apoptosis. Some studies have found that the reduction of PC and PE levels will aggravate the severity of liver histology. According to this study, a total of 792 lipids were detected in the end, and the VIP value of 98 substances was > 1. The detected substances were analyzed and verified. At the end of the day, 23 triglycerides showed a substantial difference between the two groups numerically ($P < 0.05$). Five types of PC, four types of PE, one type of PS, two types of TG, three types of sphingomyelin (SM), and one type

of glucose ceramide were all found in greater concentrations in the NASH group than in the NAFL group, and the levels of 6 kinds of TG and 1 kind of PC in NASH group were lower than those in NAFL group, and the difference was statistically significant ($P < 0.05$). This data supports the hypothesis that impaired phospholipid metabolism contributes to the development of NAFLD. Gordon believes that the increase of DAG is one of the signs of NAFLD, which may be related to the transformation of DAG to downstream products. And it can increase the pathway of PC synthesis and become a specific marker of NASH. In addition to being a part of cell membrane, sphingolipids can induce insulin resistance and lead to hepatocyte apoptosis, which has a significant impact on NAFLD development (Z. Liu et al., 2019; Ma et al., 2022; Shen et al., 2021; song, Ren, & Xu, 2020 Jan Dec; Wang et al., 2020). This study provides a comprehensive analysis of the differences in serum lipidomic profiles between athletes suffering from nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). By comparing these two groups, we have illuminated crucial distinctions in lipid metabolism that are not only diagnostic of these conditions but also potentially critical for their management within athletic populations.

4.1 Key Findings

Our findings highlight significant differences in lipid profiles between athletes with NAFLD and those with NASH, underscoring the progression of liver disease and its metabolic ramifications. Elevated levels of specific lipids such as phosphatidylcholines (PC), phosphatidylethanolamines (PE), and certain triglycerides (TG) in the NASH group suggest a distinct lipid metabolic dysregulation compared to those with NAFLD. These biomarkers offer potential targets for early detection and intervention, which is particularly important in managing athlete health, where even minor impairments can translate into significant performance declines.

4.2 Implications for Sports Medicine and Athletic Training

The differential lipid profiles observed point towards the need for tailored nutritional and training programs that consider the metabolic health and liver status of athletes. For sports medicine practitioners, these findings emphasize the importance of regular monitoring of liver health and metabolic markers in athletes, particularly those at risk or showing signs of metabolic syndrome or liver disease. Interventions that specifically address abnormal lipid metabolism could be crucial in not only improving liver health but also enhancing overall athletic performance and longevity.

4.3 Future Research Directions

While this study makes significant contributions to our understanding of lipid metabolism in athletes with liver disease, further research is needed to

establish causality and to explore the effectiveness of specific interventions. Longitudinal studies could assess the impact of targeted dietary and exercise interventions on the progression of NAFLD and NASH in athletes. Additionally, exploring genetic predispositions and lifestyle factors that may influence lipid profiles could offer more personalized approaches to prevention and treatment.

4.4 Closing Thoughts

In conclusion, our study reaffirms the critical role of lipidomics in understanding and managing liver diseases such as NAFLD and NASH in athletes. As the fields of sports medicine and metabolic health continue to converge, it becomes increasingly important to leverage advanced diagnostic and therapeutic strategies to maintain and enhance the health and performance of athletes. By integrating lipidomic profiling into routine athlete assessments, we can pave the way for more nuanced and effective health management strategies that support the long-term well-being and success of athletes across all levels of performance.

Reference

Abdelmalek, M. F. (2021). Nonalcoholic fatty liver disease: another leap forward. *Nature reviews Gastroenterology & hepatology, 18*(2), 85-86.

Bessone, F., Razori, M. V., & Roma, M. G. (2019). Molecular pathways of nonalcoholic fatty liver disease development and progression. *Cellular and Molecular Life Sciences, 76*, 99-128.

De, A., & Duseja, A. (2020). Natural history of simple steatosis or nonalcoholic fatty liver. *Journal of Clinical and Experimental Hepatology, 10*(3), 255-262.

Khalifa, O., Errafii, K., Al-Akl, N. S., & Arredouani, A. (2020). Noncoding RNAs in nonalcoholic fatty liver disease: potential diagnosis and prognosis biomarkers. *Disease Markers, 2020*, 1-16.

Liu, J., Wang, T., He, K., Xu, M., & Gong, J.-P. (2019). Cardiolipin inhibitor ameliorates the non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation. *European Review for Medical & Pharmacological Sciences, 23*(18).

Liu, Z., Wang, Y., Wang, L., Yao, B., Sun, L., Liu, R., . . . Liu, Q. (2019). Long non-coding RNA AGAP2-AS1, functioning as a competitive endogenous RNA, upregulates ANXA11 expression by sponging miR-16-5p and promotes proliferation and metastasis in hepatocellular carcinoma. *Journal of Experimental & Clinical Cancer Research, 38*, 1-15.

Ma, X., Mo, M., Tan, C., Tan, J. H. J., Huang, H., Liu, B., . . . Qiu, X. (2022). Liver-specific LINC01146, a promising prognostic indicator, inhibits the malignant phenotype of hepatocellular carcinoma cells both in vitro and in vivo. *Journal of Translational Medicine, 20*(1), 1-18.

Männistö, V., Kaminska, D., Kärjä, V., Tiainen, M., de Mello, V. D., Hanhineva, K., . . . Pihlajamäki, J. (2019). Total liver phosphatidylcholine content

associates with non-alcoholic steatohepatitis and glycine N-methyltransferase expression. *Liver International, 39*(10), 1895-1905.

Mato, J., Alonso, C., & noureddin, m. (2019). biomarkers and subtypes derived lipid metabolism in non-alcoholic fatty liver disease. *world J gastroenterol, 25*(24), 3009-3020.

Maurice, J. (2018). Manousou p.non-alcoholic fatty liver disease.clin MED (long). *18*(3), 245-250.

Mehra, M., & Chauhan, R. (2017). Long noncoding RNAs as a key player in hepatocellular carcinoma. *Biomarkers in cancer, 9*, 1179299X17737301.

Mendez-Sanchez, N., Cruz-Ramon, V. C., Ramirez-Perez, O. L., Hwang, J. P., Barranco-Fragoso, B., & Cordova-Gallardo, J. (2018). New aspects of lipotoxicity in nonalcoholic steatohepatitis. *International Journal of Molecular Sciences, 19*(7), 2034.

Pierantonelli, I., & Svegliati-Baroni, G. (2019). Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH. *Transplantation, 103*(1), e1-e13.

Pirola, C. J., & Sookoian, S. (2022). Epigenetics factors in nonalcoholic fatty liver disease. *Expert review of gastroenterology & hepatology, 16*(6), 521-536.

Polyzos, S., kountouras, J., & mantzoros, c. (2020 Mar). Obetichoic acid for the treatment of nonalcoholic steatohepatits: expectations and concerns Metabolism 104:154144.

Rusu, I., Pirlog, R., Chiroi, P., Nutu, A., Puia, V. R., Fetti, A. C., . . . Al Hajjar, N. (2022). The implications of noncoding rnas in the evolution and progression of nonalcoholic fatty liver disease (Nafld)-related hcc. *International Journal of Molecular Sciences, 23*(20), 12370.

Sargazi, S., Toudeshkchouei, M. G., Rahdar, A., Rauf, A., Amani, S., Bilal, M., . . . Baino, F. (2023). Emerging Nano-Theranostic Strategies against Non-Alcoholic Fatty Liver Disease: a review. *Iranian Journal of Materials Science & Engineering, 20*(1).

Sberna, A., Bouillet, B., Rouland, A., Brindisi, M., Nguyen, A., Mouillot, T., . . . Vergès, B. (2018). European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes. *Diabetic Medicine, 35*(3), 368-375.

Shen, C., Ding, L., Mo, H., Liu, R., Xu, Q., & Tu, K. (2021). Long noncoding RNA FIRRE contributes to the proliferation and glycolysis of hepatocellular carcinoma cells by enhancing PFKFB4 expression. *Journal of Cancer, 12*(13), 4099.

Simon, J., Ouro, A., Ala-Ibanibo, L., Presa, N., Delgado, T. C., & Martínez-Chantar, M. L. (2019). Sphingolipids in non-alcoholic fatty liver disease and hepatocellular carcinoma: ceramide turnover. *International Journal of Molecular Sciences, 21*(1), 40.

song, X., Ren, x., & Xu, X. (2020 Jan Dec). lncrna rhpn1-as1 promotes cell promotion, migration and invasion through targeting mir-7-5p and activating pi3k/akt/mtor pathway in heparocellular carcinoma. *Technol Cancer Res treat 19*.

Sun, L., & Choi, E. (2023). Substrate Transport in Cylindrical Multi-Capillary Beds with Axial Diffusion. *Letters in Biomathematics, 10*(1), 63–74.

Suppli, M. P., Rigbolt, K. T., Veidal, S. S., Heebøll, S., Eriksen, P. L., Demant, M., . . . Thrane, S. W. (2019). Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals. *American Journal of Physiology-Gastrointestinal and Liver Physiology, 316*(4), G462-G472.

Wang, M.-R., Fang, D., Di, M.-P., Guan, J.-L., Wang, G., Liu, L., . . . Li, P.-Y. (2020). Long non-coding RNA LINC01503 promotes the progression of hepatocellular carcinoma via activating MAPK/ERK pathway. *International Journal of Medical Sciences, 17*(9), 1224.

Wong, C.-M., Tsang, F. H.-C., & Ng, I. O.-L. (2018). Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications. *Nature reviews Gastroenterology & hepatology, 15*(3), 137-151.

Yela, D. A., Faber, M., Dantas, A., Benetti-pinto, C. L., & Jales, R. (2022). Difficulty in Diagnosing of Renal Choriocarcinoma: Case Report. *Jornal Brasileiro de Patologia e Medicina Laboratorial, 58*.

Younossi, Z., Tacke, F., Arrese, M., Chander Sharma, B., Mostafa, I., Bugianesi, E., . . . Fan, J. (2019). Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. *Hepatology, 69*(6), 2672-2682.

Yu, Z., Chen, T., Mo, H., Guo, C., & Liu, Q. (2020). BRD8, which is negatively regulated by miR-876–3p, promotes the proliferation and apoptosis resistance of hepatocellular carcinoma cells via KAT5. *Archives of biochemistry and biophysics, 693*, 108550.

Zaiou, M. (2022). Noncoding RNAs as additional mediators of epigenetic regulation in nonalcoholic fatty liver disease. *World journal of gastroenterology, 28*(35), 5111.

Zhang, Y., Xu, J., Zhang, S., An, J., Zhang, J., Huang, J., & Jin, Y. (2018). HOXA-AS2 promotes proliferation and induces epithelial-mesenchymal transition via the miR-520c-3p/GPC3 axis in hepatocellular carcinoma. *Cellular Physiology and Biochemistry, 50*(6), 2124-2138.

Zhou, J., Shi, K., Huang, W., Zhang, Y., Chen, Q., Mou, T., . . . Wei, X. (2023). LncRNA RPPH1 acts as a molecular sponge for miR-122 to regulate Wnt1/β-catenin signaling in hepatocellular carcinoma. *International Journal of Medical Sciences, 20*(1), 23.

Zhou, Q., Zhang, W., Wang, Z., & Liu, S. (2019). Long non-coding RNA PTTG3P functions as an oncogene by sponging miR-383 and up-regulating CCND1 and PARP2 in hepatocellular carcinoma. *BMC cancer, 19*(1), 1-11.